Abstract
Epigallocatechin‑3‑gallate (EGCG), a polyphenol present in green tea, exhibits anticancer effects in various types of cancer. This study investigates its impact on ovarian cancer, specifically targeting the PTEN/AKT/mTOR signaling pathway. Our findings reveal that EGCG significantly inhibits proliferation and induces apoptosis in SKOV3 ovarian cancer cells, outperforming its effects on lung cancer cells. In vivo experiments further demonstrate that high-dose EGCG (50 mg/kg) suppresses tumor growth more effectively than the standard chemotherapy drug paclitaxel. These results suggest EGCG as a promising candidate for ovarian cancer therapy.
Introduction
Ovarian cancer remains one of the most lethal gynecological malignancies, largely because it is often diagnosed at advanced stages when the 5-year survival rate is only about 40%. While the standard treatment involves surgery followed by platinum and paclitaxel chemotherapy, these drugs often lead to significant toxicity and the eventual development of drug resistance.
Researchers have long known that EGCG has anticancer properties, particularly in lung cancer, but its efficacy and specific molecular mechanisms in ovarian cancer were previously poorly understood. This study set out to determine if EGCG could serve as a low-toxicity alternative or supplement by targeting the PTEN/AKT/mTOR pathway—a signaling axis that is overactive in more than 70% of ovarian cancer cases.
Methods
The researchers employed a multi-tiered experimental approach to validate EGCG's efficacy:
- In Vitro Screening: Testing EGCG on several ovarian cancer cell lines (SKOV3, CAOV-3, NIH-OVCAR-3) compared against lung cancer cells (A549) and normal human retinal cells (RPE) to assess selectivity.
- Cellular Assays: MTT assays for cell viability, colony formation assays for long-term proliferative potential, and flow cytometry to quantify apoptosis.
- Molecular Analysis: RT-qPCR and Western blotting to measure the expression of key genes and proteins in the PTEN/AKT/mTOR pathway, including Bax, Bcl-2, and caspase-3.
- Pathway Validation: Use of a specific PTEN inhibitor (VO-Ohpic trihydrate) to confirm the signaling hierarchy.
- In Vivo Xenografts: Implanting SKOV3 cells into nude mice to test EGCG’s performance in a living system against a paclitaxel control.
Results
Potent Inhibition of Ovarian Cancer Cells
EGCG demonstrated a potent, dose-dependent inhibitory effect on the viability of ovarian cancer cell lines. Interestingly, EGCG showed a stronger inhibitory effect on ovarian cancer cells (SKOV3) than on lung cancer cells (A549), suggesting it might be particularly well-suited for this malignancy. The $IC_{50}$ for SKOV3 cells was approximately 26.07 µg/ml at 48 hours.
Beyond immediate viability, EGCG also significantly impaired the long-term proliferative capacity of these cells. Colony formation assays showed a marked reduction in the number and size of cancer colonies at concentrations as low as 10 µg/ml, with near-complete suppression at 20 µg/ml.
The PTEN/AKT/mTOR Mechanism
The study identifies PTEN upregulation as the primary driver of EGCG’s success. By increasing PTEN levels, EGCG effectively "turns off" the downstream PDK1/AKT/mTOR signaling that usually tells cancer cells to grow and survive. Western blots confirmed that EGCG significantly increased PTEN protein levels while decreasing the phosphorylated (active) forms of AKT and mTOR. This mechanism was validated when the PTEN inhibitor VO-Ohpic trihydrate successfully reversed EGCG's anti-proliferative effects.
Superior In Vivo Performance
In the mouse xenograft model, 50 mg/kg EGCG reduced tumor weight by 71.25%, whereas the standard dose of paclitaxel (5 mg/kg) only achieved a 39.62% reduction. Crucially, EGCG exhibited minimal toxicity toward normal cells and the mice tolerated the treatment well without significant weight loss.
Conclusion
This study provides a compelling mechanistic basis for using green tea derivatives as a potential low-toxicity strategy in the fight against ovarian cancer. By targeting the PTEN/AKT/mTOR axis, EGCG offers a promising therapeutic window. While moving from mouse xenografts to human clinical trials is a significant leap, these findings establish EGCG as a strong candidate for further drug development.
Summary updated